Featured

Status

All Statuses
  • Withdrawn6

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

6 Results
Withdrawn
Acthar on Proteinuria in IgA Nephropathy Patients
Participation in this study may last up to 2 years (from first visit to final visit) and includes 10 study visits and 8 phone calls. Subjects will be randomly assigned …
Baylor Role: Lead Sponsor
Withdrawn
Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension
The purpose of the study is to find out if taking a dose of gabapentin 600 mg by mouth (po) before surgery will help prevent the development of tourniquet pain …
Baylor Role: Lead Sponsor
Withdrawn
A Study of Bevacizumab to Prevent Malignant Ascites
All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study. The primary …
Baylor Role: Lead Sponsor
Withdrawn
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
While patients with nasopharyngeal carcinoma (NPC) may be cured by chemotherapy and radiotherapy, the outlook for patients who are resistant to this treatment or who relapse is poor. Almost all …
Baylor Role: Lead Sponsor
Withdrawn
Rituximab for GVHD
Acute graft-versus-host disease (aGVHD), one of the most important complications of allogeneic hematopoietic stem cell transplantation (HSCT) is associated with significant morbidity and mortality. Grades II to IV aGVHD occur …
Baylor Role: Lead Sponsor
Withdrawn
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
This is a phase I trial to assess the safety of depleting regulatory T (Treg) cells using 1-3 doses of an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, …
Baylor Role: Lead Sponsor